Efficient Transdermal Delivery of Benfotiamine in an Animal Model

We designed a transdermal system to serve as a delivery platform for benfotiamine utilizing the attributes of passive penetration enhancing molecules to penetrate through the outer layers of skin combined with the advance of incorporating various peripherally-acting vasodilators to enhance drug upta...

Full description

Bibliographic Details
Main Authors: Gyula Varadi, Zhen Zhu, Stephen G. Carter
Format: Article
Language:English
Published: International Association of Physical Chemists (IAPC) 2015-01-01
Series:ADMET and DMPK
Online Access:http://pub.iapchem.org/ojs/index.php/admet/article/view/130
id doaj-cc9a0041d2f444d08c35a0ebcfd8a3c5
record_format Article
spelling doaj-cc9a0041d2f444d08c35a0ebcfd8a3c52020-11-24T20:49:05ZengInternational Association of Physical Chemists (IAPC)ADMET and DMPK1848-77182015-01-012427228110.5599/admet.2.4.130113Efficient Transdermal Delivery of Benfotiamine in an Animal ModelGyula Varadi0Zhen Zhu1Stephen G. Carter2BioChemics, Inc.BioChemics, Inc.BioChemics, Inc.We designed a transdermal system to serve as a delivery platform for benfotiamine utilizing the attributes of passive penetration enhancing molecules to penetrate through the outer layers of skin combined with the advance of incorporating various peripherally-acting vasodilators to enhance drug uptake.  Benfotiamine, incorporated into this transdermal formulation, was applied to skin in an animal model in order to determine the ability to deliver this thiamine pro-drug effectively to the sub-epithelial layers.  In this proof of concept study in guinea pigs, we found that a single topical application of either a solubilized form of benfotiamine (15 mg) or a microcrystalline suspension form (25 mg) resulted in considerable increases of the dephosphorylated benfotiamine (S-benzoylthiamine) in the skin tissue as well as in significant increases in the thiamine and thiamine phosphate pools compared to control animals.  The presence of a ~8000x increase in thiamine and increases in its phosphorylated derivatives in the epidermis and dermis tissue of the test animals gives a strong indication that the topical treatment with benfotiamine works very well for the desired outcome of producing an intracellular increase of the activating cofactor pool for transketolase enzyme, which is implicated in the pathophysiology of diabetic neuropathy.http://pub.iapchem.org/ojs/index.php/admet/article/view/130
collection DOAJ
language English
format Article
sources DOAJ
author Gyula Varadi
Zhen Zhu
Stephen G. Carter
spellingShingle Gyula Varadi
Zhen Zhu
Stephen G. Carter
Efficient Transdermal Delivery of Benfotiamine in an Animal Model
ADMET and DMPK
author_facet Gyula Varadi
Zhen Zhu
Stephen G. Carter
author_sort Gyula Varadi
title Efficient Transdermal Delivery of Benfotiamine in an Animal Model
title_short Efficient Transdermal Delivery of Benfotiamine in an Animal Model
title_full Efficient Transdermal Delivery of Benfotiamine in an Animal Model
title_fullStr Efficient Transdermal Delivery of Benfotiamine in an Animal Model
title_full_unstemmed Efficient Transdermal Delivery of Benfotiamine in an Animal Model
title_sort efficient transdermal delivery of benfotiamine in an animal model
publisher International Association of Physical Chemists (IAPC)
series ADMET and DMPK
issn 1848-7718
publishDate 2015-01-01
description We designed a transdermal system to serve as a delivery platform for benfotiamine utilizing the attributes of passive penetration enhancing molecules to penetrate through the outer layers of skin combined with the advance of incorporating various peripherally-acting vasodilators to enhance drug uptake.  Benfotiamine, incorporated into this transdermal formulation, was applied to skin in an animal model in order to determine the ability to deliver this thiamine pro-drug effectively to the sub-epithelial layers.  In this proof of concept study in guinea pigs, we found that a single topical application of either a solubilized form of benfotiamine (15 mg) or a microcrystalline suspension form (25 mg) resulted in considerable increases of the dephosphorylated benfotiamine (S-benzoylthiamine) in the skin tissue as well as in significant increases in the thiamine and thiamine phosphate pools compared to control animals.  The presence of a ~8000x increase in thiamine and increases in its phosphorylated derivatives in the epidermis and dermis tissue of the test animals gives a strong indication that the topical treatment with benfotiamine works very well for the desired outcome of producing an intracellular increase of the activating cofactor pool for transketolase enzyme, which is implicated in the pathophysiology of diabetic neuropathy.
url http://pub.iapchem.org/ojs/index.php/admet/article/view/130
work_keys_str_mv AT gyulavaradi efficienttransdermaldeliveryofbenfotiamineinananimalmodel
AT zhenzhu efficienttransdermaldeliveryofbenfotiamineinananimalmodel
AT stephengcarter efficienttransdermaldeliveryofbenfotiamineinananimalmodel
_version_ 1716806845112254464